Dendritic Cell Cancer Vaccine Market Report 2026

Dendritic Cell Cancer Vaccine Market Overview

• Dendritic Cell Cancer Vaccine market size has reached to $2.71 billion in 2025 • Expected to grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Number Of Cancer Cases Boosts Growth Of Dendritic Cell Cancer Vaccine Market • Market Trend: Strategic Collaboration To Develop Cancer Curatives • North America was the largest region in 2025.

What Is Covered Under Dendritic Cell Cancer Vaccine Market?

Dendritic cell cancer vaccines are immunotherapies that utilize the body's dendritic cells to stimulate an immune response against cancer cells, potentially enhancing the body's ability to recognize and destroy tumors. They are used as a personalized treatment approach to target specific types of cancer and bolster the immune system's ability to combat the disease. Dendritic cell cancer vaccines harness the body's immune system to fight against cancer cells, potentially leading to more effective and durable responses in patients. The main products of dendritic cell cancer vaccine are CreaVax, Sipuleucel-T (Provenge), and others. CreaVax refers to a dendritic cell cancer vaccine designed to activate the body's immune response against cancer cells by using specialized immune cells loaded with tumor-specific antigens. The distribution channel includes hospitals, cancer centers, ambulatory surgical centers, and clinics. The applications are for pediatrics and adults. Various end users include oncology, research institutions, and biopharmaceutical companies.

What Is The Dendritic Cell Cancer Vaccine Market Growth Forecast?

The dendritic cell cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to advancements in cell therapy manufacturing, expansion of precision oncology, increasing regulatory support, rising cancer incidence, growing investment in immunotherapy pipelines. Major trends in the forecast period include growth of personalized cancer vaccines, expansion of clinical trials in solid tumors, increased focus on immune system modulation, rising adoption of combination immunotherapies, advancements in cell processing technologies.

Global Dendritic Cell Cancer Vaccine Market Segmentation

1) By Product: CreaVax, Sipuleucel-T (Provenge), Other Products 2) By Distribution Channel: Hospitals, Cancer Centers, Ambulatory Surgical Centers, Clinics 3) By Application: Pediatrics, Adults 4) By End User: Oncology, Research Institutions, Biopharmaceutical Companies Subsegments: 1) By Creavax: Creavax In Clinical Trials, Creavax Commercialization 2) By Sipuleucel-T (Provenge): Sipuleucel-T In Prostate Cancer, Sipuleucel-T Market Share, Sipuleucel-T Regulatory Approvals 3) By Other Products: Dcvax, Oncovax, GVAX

What Is The Driver Of The Dendritic Cell Cancer Vaccine Market?

The rising number of cancer cases is expected to propel the growth of the dendritic cell cancer vaccine market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, often leading to the formation of tumors and disruption of normal bodily functions. The number of cancer cases is impacted by factors related to lifestyle choices, environmental exposures, and genetic predispositions. Dendritic cell cancer vaccines are utilized in cancer treatment to stimulate the body's immune system, targeting cancer cells and potentially improving patient outcomes. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising number of cancer cases is driving the growth of the dendritic cell cancer vaccine industry.

Key Players In The Global Dendritic Cell Cancer Vaccine Market

Major companies operating in the dendritic cell cancer vaccine market are Dendreon Pharmaceuticals LLC, Cognate BioServices Inc., Batavia Biosciences, Medigene AG, Zelluna Immunotherapy AS, Northwest Biotherapeutics, PDC*line Pharma SA, ImmunityBio Inc., Celldex Therapeutics Inc., Argos Therapeutics Inc., DCPrime, NuGenerex Immuno‑Oncology, ImmunoCellular Therapeutics Ltd., Immunicum AB, 3M Company, Activartis Biotech GmbH, DanDrit Biotech, Kiromic BioPharma Inc., GlaxoSmithKline plc, SOTIO, Vaxil BioTherapeutics

Global Dendritic Cell Cancer Vaccine Market Trends and Insights

Major companies operating in the dendritic cell cancer vaccine market are focused on forming strategic collaborations to develop cancer curative vaccines to advance better clinical care to patients. Strategic collaborations refer to formal partnerships between companies or organizations aimed at achieving specific business objectives that are mutually beneficial. For instance, in May 2023, Walter and Eliza Hall Institute of Medical Research, an Australia-based medical research institute, collaborated with Peter MacCallum Cancer Centre, an Australia-based oncology research institute. They have received over $900,000 in MRFF funding to create a cancer vaccine for patients with few therapeutic alternatives. The team seeks to improve dendritic cell-based vaccinations, a potential treatment for cancer patients that includes boosting their cells to fight cancer. This study is based on a groundbreaking discovery made at WEHI 30 years ago, which could lead to the first clinical trial for cancer patients.

What Are Latest Mergers And Acquisitions In The Dendritic Cell Cancer Vaccine Market?

In November 2023, AbbVie Inc., a US-based biotech company, acquired ImmunoGen, Inc. for an undisclosed amount. With this acquisition, AbbVie Inc. aims to expand its portfolio of innovative therapies and strengthen its position in the oncology market. ImmunoGen, Inc. is a US-based biotechnology company that manufactures antibody-drug conjugates (ADCs) for cancer treatment.

Regional Outlook

North America was the largest region in the dendritic cell cancer vaccine market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Dendritic Cell Cancer Vaccine Market?

The dendritic cell cancer vaccines market consists of sales of autologous dendritic cell vaccines, allogeneic dendritic cell vaccines, and experimental vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dendritic Cell Cancer Vaccine Market Report 2026?

The dendritic cell cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dendritic cell cancer vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.